Inventor · disambiguated record
Steven Mischke
Also filed as: MISCHKE STEVEN · MISCHKE STEVEN GREGORY
28 granted patents·7 pending applications·99 citations·filing 1999–2024
95Inventor score
Files withHOFFMANN LA ROCHE16FORMA THERAPEUTICS INC14SAGE THERAPEUTICS INC2VALO HEALTH INC2VALO EARLY DISCOVERY INC1
Top patents by PatentIndex Score
35 records- 0194US10870648B2Inhibiting CREB binding protein (CBP)FORMA THERAPEUTICS INC·Filed 2019·Granted Dec 22, 2020·8 cites·24 claims
- 0291US11254674B2Inhibiting CREB binding protein (CBP)FORMA THERAPEUTICS INC·Filed 2020·Granted Feb 22, 2022·2 cites·21 claims
- 0390US11814386B2Fused pyrrolines which act as ubiquitin-specific protease 30 (USP30) inhibitorsFORMA THERAPEUTICS INC·Filed 2022·Granted Nov 14, 2023·1 cites·20 claims
- 0490US7060713B2Substituted piperidinesHOFFMANN LA ROCHE·Filed 2005·Granted Jun 13, 2006·16 cites·10 claims
- 0588US11247987B2Inhibiting ubiquitin specific peptidase 30FORMA THERAPEUTICS INC·Filed 2018·Granted Feb 15, 2022·3 cites·24 claims
- 0684US11535618B2Fused pyrrolines which act as ubiquitin-specific protease 30 (USP30) inhibitorsFORMA THERAPEUTICS INC·Filed 2019·Granted Dec 27, 2022·2 cites·21 claims
- 0783US10889592B2Thienopyrazine carboxamides as ubiquitin-specific protease inhibitorsVALO EARLY DISCOVERY INC·Filed 2017·Granted Jan 12, 2021·2 cites·28 claims
- 0882US6916833B2Substituted piperidinesHOFFMANN LA ROCHE·Filed 2004·Granted Jul 12, 2005·15 cites·25 claims
- 0980US10913753B2Thienopyridine carboxamides as ubiquitin-specific protease inhibitorsFORMA THERAPEUTICS INC·Filed 2017·Granted Feb 9, 2021·2 cites·20 claims
- 1079US2024150349A1Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitorsFORMA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1178US11292791B2Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Apr 5, 2022·1 cites·20 claims
- 1278US2024132499A1Fused pyrrolines which act as ubiquitin-specific protease 30 (usp30) inhibitorsFORMA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1377US2025188079A1Inhibiting cyclic amp-responsive element-binding protein (creb)FORMA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1475US7132425B25-substituted-six-membered heteroaromatic glucokinase activatorsHOFFMANN LA ROCHE·Filed 2003·Granted Nov 7, 2006·9 cites·93 claims
- 1574US12378242B2Inhibiting CREB binding protein (CBP)FORMA THERAPEUTICS INC·Filed 2022·Granted Aug 5, 2025·0 cites·19 claims
- 1673US11787803B2Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitorsFORMA THERAPEUTICS INC·Filed 2022·Granted Oct 17, 2023·0 cites·20 claims
- 1771US6130239A4-Alkenyl- and 4-alkynyloxindolesHOFFMANN LA ROCHE·Filed 1999·Granted Oct 10, 2000·27 cites·42 claims
- 1868US7067529B2Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitorsHOFFMANN LA ROCHE·Filed 2004·Granted Jun 27, 2006·4 cites·22 claims
- 1967US2022185806A1Inhibiting ubiquitin specific peptidase 30FORMA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2065US2024366581A1Benzimidazole pyridine derivativesHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 2164US2023312522A1Cyp46a1 inhibitors and methods of use thereofSAGE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2262US12351577B2Inhibiting cyclic AMP-responsive element-binding protein (CREB)FORMA THERAPEUTICS INC·Filed 2020·Granted Jul 8, 2025·0 cites·19 claims
- 2362US11325917B2Thienopyrazine carboxamides as ubiquitin-specific protease inhibitorsVALO HEALTH INC·Filed 2020·Granted May 10, 2022·0 cites·20 claims
- 2460US6197804B14,5-azolo-oxindolesHOFFMANN LA ROCHE·Filed 2000·Granted Mar 6, 2001·3 cites·17 claims
- 2557US12252490B2Inhibiting deubiquitinase USP25 and USP28VALO HEALTH INC·Filed 2019·Granted Mar 18, 2025·0 cites·15 claims
- 2653US8044213B2Thiazolyl-benzimidazolesHOFFMANN LA ROCHE·Filed 2009·Granted Oct 25, 2011·0 cites·15 claims
- 2751US7612212B2Substituted hydantoinsHOFFMANN LA ROCHE·Filed 2007·Granted Nov 3, 2009·0 cites·16 claims
- 2850US2022332699A1Compounds, compositions, and methods of useSAGE THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2948US6313310B14-and 5-alkynyloxindoles and 4-and 5-alkenyloxindolesHOFFMANN LA ROCHE·Filed 1999·Granted Nov 6, 2001·4 cites·51 claims
- 3047US7037924B2Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitorsHOFFMANN LA ROCHE·Filed 2004·Granted May 2, 2006·0 cites·21 claims
- 3146US7803816B2MCH receptor antagonistsHOFFMANN LA ROCHE·Filed 2006·Granted Sep 28, 2010·0 cites·16 claims
- 3245US9611224B2Antiproliferative benzo [B] azepin-2-onesHOFFMANN LA ROCHE·Filed 2013·Granted Apr 4, 2017·0 cites·42 claims
- 3345US9409888B2Dimeric compoundsHOFFMANN LA ROCHE·Filed 2013·Granted Aug 9, 2016·0 cites·14 claims
- 3444US9422332B2Azaheterocycles as BIR2 and/or BIR3 inhibitorsHOFFMANN LA ROCHE·Filed 2013·Granted Aug 23, 2016·0 cites·23 claims
- 3532US6153634A4,5-azolo-oxindolesHOFFMANN LA ROCHE·Filed 1999·Granted Nov 28, 2000·0 cites·23 claims
Join the waitlist — get patent alerts
Get an alert when Steven Mischke files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →